Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.
Talk to the deal team
Related deals
DierenDokters has been acquired by VetPartners
DierenDokters, a leading group of fourteen veterinary clinics located across the Netherlands, has been acquired by VetPartners, a UK-based group of over 650 veterinary clinics and hospitals located across Europe. By partnering with VetPartners, DierenDokters welcomes a strong new shareholder that will help further enhance DierenDokters’ clinics’ service offering and allow the clinics to continue focusing on providing the best possible animal healthcare services.
Learn moreConnexicon Medical has been acquired by Advanced Medical Solutions PLC
Connexicon Medical Ltd has been sold to Advanced Medical Solutions PLC.
Learn moreTherapy Equipment has been acquired by ESAB Corporation
Owner Venture Managers has sold Therapy Equipment Ltd. to ESAB Corporation.
Learn more